Digital programs to improve wellbeing in newly diagnosed cancer patients
Changing Mindsets to Improve Whole Patient Health: A Randomized Controlled Trial of a Novel mHealth Intervention for People Diagnosed With Cancer
This study tests two online programs designed to help newly diagnosed cancer patients improve their health and wellbeing.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 440 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT06705218 on ClinicalTrials.gov |
What this trial studies
This clinical trial tests the effects of two digitally delivered programs on the health and wellbeing of newly diagnosed cancer patients. Participants will be randomized into one of the two programs and will complete questionnaires to track their progress. They will also have access to digital courses developed by experts at Stanford University and will provide blood samples using at-home collection kits to monitor their physiological responses over time. The aim is to address the psychological and physical challenges faced by cancer patients through scalable interventions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a recent diagnosis of non-metastatic cancer who are currently receiving or planning to receive systemic treatment.
Not a fit: Patients with severe mental health conditions such as severe depression or schizophrenia may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance the quality of life and overall wellbeing of cancer patients during their treatment.
How similar studies have performed: While there is growing evidence supporting the connection between mental and physical health in cancer care, this specific approach using digital interventions is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Initial (non-recurrent) diagnosis of non-metastatic (stage I-III) or hematological malignancy. * Diagnosis in the past 150 days. * Currently receiving active systemic treatment or with a planned systemic treatment (including chemotherapy, immunotherapy or other targeted therapies). * Eighteen years of age or older. * Fluent in English. * Currently reside in the United States. * Access to a computer, tablet, or smartphone (a mobile phone that performs many of the functions of a computer, typically including a touchscreen interface, internet access, and an operating system capable of running downloaded applications, or tablet that runs iOS or Android software, with cellular data service or wifi access). Exclusion Criteria: * Failure to meet inclusion criteria. * Currently receiving treatment for severe depression, severe anxiety, bipolar disorder, post-traumatic stress disorder, or schizophrenia.
Where this trial is running
Palo Alto, California
- Stanford University — Palo Alto, California, United States (Recruiting)
Study contacts
- Principal investigator: Alia J Crum, PhD — Stanford University
- Study coordinator: Study Coordinator
- Email: embracestudy@stanford.edu
- Phone: (650) 476-3868
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.